Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03943875 · ClinicalTrials.gov registry record · Phase 4
GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose
A Phase 4 study of Human Papilloma Virus and Immunization, sponsored by The University of Texas Medical Branch, Galveston.
- Active
- Registry status
- Phase 4
- Development phase
- 767
- Enrollment target
- 1
- Study location
NCT03943875 is a Phase 4 study of Human Papilloma Virus and Immunization that is active but no longer recruiting, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 767 participants, above the 595-participant average among 26 other Human Papilloma Virus trials with a reported enrollment target (29% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03943875, a Phase 4 study of Human Papilloma Virus and Immunization, is active but no longer recruiting, sponsored by The University of Texas Medical Branch, Galveston.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 767 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators are evaluating whether 15-26 year old males and females need a 3rd dose of the human papillomavirus (HPV) vaccine, or whether 2 doses provide similar protection as 3 doses from the 9 types of HPV that it protects against.
Conditions Studied
Interventions
- BIOLOGICAL 9-valent HPV vaccine, 3 doses standard timing
- BIOLOGICAL 9-valent HPV vaccine, 2 dose efficacy
Study Locations (1)
Texas
- University of Texas Medical Branch - Galveston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 767 participants |
| Start Date | 2019-06-17 |
| Est. Completion | 2026-03-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03943875
The ClinicalTrials.gov registry entry for NCT03943875 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 767 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 595-participant average among 26 other Human Papilloma Virus trials with a reported enrollment target (29% higher). The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Human Papilloma Virus appearing as the primary indexed condition, and to 2 interventions - of which 9-valent HPV vaccine, 3 doses standard timing is the first listed.
NCT03943875 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03943875 about?
NCT03943875 is a clinical study titled "GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose". The investigators are evaluating whether 15-26 year old males and females need a 3rd dose of the human papillomavirus (HPV) vaccine, or whether 2 doses provide similar protection as 3 doses from the 9 types of HPV that it protects against.
What is the current status of trial NCT03943875?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 767 participants. The study started on 2019-06-17. Estimated completion is 2026-03-01.
What conditions does trial NCT03943875 study?
This clinical trial studies the following conditions: Human Papilloma Virus, Immunization, Efficacy.
What interventions are being tested in trial NCT03943875?
The interventions under investigation include: 9-valent HPV vaccine, 3 doses standard timing (BIOLOGICAL), 9-valent HPV vaccine, 2 dose efficacy (BIOLOGICAL).
Who is sponsoring clinical trial NCT03943875?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03943875 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papilloma Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Educate and Improve Underserved Populations' Uptake and Completion of the HPV Vaccine
RECRUITING · NA
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
Multidimensional and Multimodal Profiling of Oropharyngeal Carcinoma
RECRUITING
-
Merck IIT: RRP Pembro and Lenvatinib
RECRUITING · Early Phase 1
-
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.